Investments

Magimix, founded in 1971, is a premier brand specializing in high-quality small kitchen appliances for home cooking. Renowned for its innovative food processors, blenders, juicers, and coffee machines, particularly through its collaboration with Nespresso, Magimix is synonymous with reliability and performance. Operating primarily in France, the UK, and the Netherlands, Magimix serves a diverse customer base that includes specialized retailers and department stores, complemented by a robust online presence. The brand is committed to innovation and quality, ensuring that its products enhance the cooking experience for home chefs. As part of a strategic partnership with Ardian and the Hameur Group, Magimix is set to pursue accelerated growth and international expansion, focusing on developing new products and strengthening its market presence.

Robot-Coupe, founded in 1961 in Burgundy, France, is the global leader in premium benchtop equipment for professional kitchens. Well-known for its reliability and Made-in-France quality, the brand has become essential in over 130 countries, serving more than 7,000 distributors and importers. Robot-Coupe holds leading market shares in key regions, including the US, France, Australia, and the UK.
The company offers a diverse product portfolio that includes food processors, vegetable preparators, juicers, and blenders, designed for efficiency and versatility in food preparation. With three manufacturing sites in France, the US, and Sweden, Robot-Coupe is committed to innovation and addressing chefs' needs for robust, user-friendly equipment.

Masco Group is a leading global provider of engineered solutions and services for the life sciences industry, particularly focused on the rapidly growing biologics market. Founded in 1912 and headquartered in Milan, the company is specialized in high-purity water systems, bioprocessing equipment, modular off-site fabricated facilities, and a range of value-added services. With a strong track record of over 100 years, Masco Group has established significant brand recognition, particularly through its brand Stilmas. The company has expanded its portfolio through four strategic acquisitions since 2017, enhancing its capabilities in bioprocessing and modular facilities.
Masco’s solutions are critical to large biopharma companies and contract development and manufacturing organizations (CDMOs) across more than 80 countries. The company operates seven manufacturing facilities located in Europe, North America, and Asia, employing over 800 professionals and generating revenues exceeding €300 million.

Neopharmed Gentili represents the spin-off of the primary care business of Mediolanum Farmaceutici Group and is a leading pharmaceutical company in the Italian market focused on branded prescription drugs in cardiovascular, neurology and allergo-respiratory therapeutic areas, with a portfolio of off-patent and mostly proprietary products. Its flexible and asset-light business model makes Neopharmed Gentili an attractive commercial platform with a proprietary, reliable, and specialized sales force of over 400 pharma representatives.

Aire Networks, founded in 2002 by Raul Aledo, Miguel Tecles and Emilio Gras, is Iberia’s leading neutral B2B provider of ICT services (Data and Mobile connectivity and Cloud solutions) for resellers/alternative operators (virtual, local, national and international carriers) and corporate markets (from SMEs and large companies to hyperscalers) delivered through an extensive asset-light footprint.

Created from the consolidation of several regional insurance brokers, Odealim is the first specialist in real estate insurance brokerage and credit brokerage on the French market today.
With a strong geographical footprint and a powerful network of partner insurers, Odealim can guarantee to its customers, professionals and individuals, a complementary support and customized solutions.

Biofarma is the global leading player in the development, manufacturing, and packaging of health supplements, medical devices and cosmetics for large Pharma and CPG clients.
Biofarma offers its clients an integrated offer, from market intelligence, R&D and regulatory support, to manufacturing and packaging of finished dosage form products. Biofarma differentiates itself for its capacity to develop and proactively offer its clients innovative solutions by combining differentiated manufacturing technologies, delivery systems, and formulation capabilities. In addition, Biofarma has a strong expertise in probiotics and has an innovative portfolio of Medical Devices, supported by clinical studies and for which it owns dossiers.
As a result of this differentiated positioning, Biofarma is the partner-of-choice of large Pharma and Consumer Health (‘CHCs’) clients for co-development projects requiring strong innovation capabilities, international regulatory capabilities, and manufacturing quality reliability.